Company Performance - Evolv Technologies Holdings, Inc. reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of -177.78% [1] - The company posted revenues of $32.54 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 11.26%, compared to revenues of $25.54 million a year ago [2] - Over the last four quarters, Evolv Technologies has surpassed consensus EPS estimates only once [2] Stock Movement and Outlook - Evolv Technologies shares have increased approximately 89.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 10% [3] - The future price movement of the stock will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $31.99 million, and for the current fiscal year, it is -$0.23 on revenues of $126.22 million [7] Industry Context - The Computers - IT Services industry, to which Evolv Technologies belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Evolv Technologies' performance [5][6]

Group 1 - MeiraGTx Holdings PLC reported a quarterly loss of $0.48 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.76 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company posted revenues of $3.69 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 59.78%, compared to revenues of $0.28 million in the same quarter last year [2] - MeiraGTx shares have increased approximately 37% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] Group 2 - The earnings outlook for MeiraGTx is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.53 on revenues of $2.77 million, and -$0.71 on revenues of $59.52 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Clene Inc., another company in the same industry, is expected to report a quarterly loss of $0.49 per share, reflecting a year-over-year change of +53.8%, with revenues anticipated to be $0.1 million, up 11.1% from the previous year [9]

Core Viewpoint - MediWound reported a quarterly loss of $1.23 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.55, marking an earnings surprise of -123.64% [1] - The company posted revenues of $5.71 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1.89% and showing growth from $5.06 million a year ago [2] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.64 on revenues of $6.68 million, and for the current fiscal year, it is -$1.99 on revenues of $23.97 million [7] Stock Performance - MediWound shares have increased by approximately 5.3% since the beginning of the year, compared to a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Outlook - The Medical - Drugs industry is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Insights - Applied Industrial Technologies (AIT) reported quarterly earnings of $2.8 per share, exceeding the Zacks Consensus Estimate of $2.6 per share, and showing an increase from $2.64 per share a year ago, resulting in an earnings surprise of +7.69% [1] - The company achieved revenues of $1.22 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.74% and up from $1.16 billion year-over-year [2] - AIT's shares have increased approximately 15.1% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.52 on revenues of $1.16 billion, while for the current fiscal year, the estimate is $10.52 on revenues of $4.77 billion [7] - The estimate revisions trend for AIT was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Manufacturing - General Industrial industry, to which AIT belongs, is currently ranked in the top 14% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1 - Golar LNG reported quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.29 per share, and down from $0.42 per share a year ago, representing an earnings surprise of -10.34% [1] - The company posted revenues of $75.67 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 14.20%, compared to year-ago revenues of $62.98 million [2] - Golar LNG shares have lost about 5% since the beginning of the year, while the S&P 500 has gained 10% [3] Group 2 - The earnings outlook for Golar LNG is uncertain, with current consensus EPS estimates of $0.55 on $121.38 million in revenues for the coming quarter and $1.47 on $375.67 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Oil and Gas - Integrated - International is currently in the bottom 24% of over 250 Zacks industries, indicating potential challenges for the sector [8] - New Fortress Energy, another company in the same industry, is expected to report a quarterly loss of $0.29 per share, with revenues projected to be $686.21 million, up 60.3% from the year-ago quarter [9]

Group 1: Earnings Performance - Amcor reported quarterly earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.21 per share, and down from $0.21 per share a year ago, representing an earnings surprise of -4.76% [1] - The company posted revenues of $5.08 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.76%, and up from $3.54 billion year-over-year [2] - Over the last four quarters, Amcor has not surpassed consensus EPS or revenue estimates [2] Group 2: Stock Performance and Outlook - Amcor shares have increased by approximately 5.6% since the beginning of the year, compared to a 10% gain in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.20 on revenues of $5.86 billion, and for the current fiscal year, it is $0.82 on revenues of $23.6 billion [7] Group 3: Industry Context - The Containers - Paper and Packaging industry, to which Amcor belongs, is currently ranked in the bottom 19% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Amcor's stock performance [5][6]

Company Performance - VAXART, INC. reported a quarterly loss of $0.07 per share, which was better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of +22.22% [1] - The company posted revenues of $39.73 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 1,206.91%, compared to revenues of $6.4 million in the same quarter last year [2] - Over the last four quarters, VAXART has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - VAXART shares have declined approximately 42.6% since the beginning of the year, while the S&P 500 has gained 9.6% [3] - The current Zacks Rank for VAXART is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $3.29 million, and for the current fiscal year, it is -$0.28 on revenues of $24.15 million [7] - The outlook for the Medical - Drugs industry, to which VAXART belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

分组1 - IceCure Medical Ltd. reported quarterly earnings of $0.06 per share, surpassing the Zacks Consensus Estimate of a loss of $0.06 per share, representing an earnings surprise of +200.00% [1] - The company posted revenues of $0.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 34.38%, and a decline from $1.01 million in the same quarter last year [2] - IceCure Medical shares have decreased by approximately 25.5% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.06 on $1 million in revenues, and for the current fiscal year, it is -$0.20 on $6.85 million in revenues [7] - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 39% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

分组1 - Ovid Therapeutics reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.16, representing an earnings surprise of +62.50% [1] - The company posted revenues of $6.27 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4,225.52%, compared to revenues of $0.17 million a year ago [2] - Ovid Therapeutics has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 41.4% since the beginning of the year, while the S&P 500 gained 9.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.14 on $0.1 million in revenues, and for the current fiscal year, it is -$0.60 on $0.52 million in revenues [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Company Performance - Sanara MedTech Inc. reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.33, and an improvement from a loss of $0.41 per share a year ago, representing an earnings surprise of +30.30% [1] - The company posted revenues of $25.83 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.70%, and showing an increase from $20.16 million in the same quarter last year [2] - Over the last four quarters, Sanara MedTech has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Sanara MedTech shares have declined approximately 17.3% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] - The current Zacks Rank for Sanara MedTech is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of $26.65 million, and for the current fiscal year, it is -$1.56 on revenues of $106.93 million [7] - The trend of estimate revisions for Sanara MedTech was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which Sanara MedTech belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]